BACKGROUND:Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied. STUDY DESIGN: Post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. SETTING & PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial of 5,608 men and 997 women without CVD randomly assigned to treatment withlovastatin or placebo. INTERVENTION: Placebo or lovastatin, 20 mg/d. OUTCOMES & MEASUREMENTS: First major acute cardiovascular event in participants with mild CKD and kidney function loss in persons with or without CKD. Estimated glomerular filtration rate was calculated using the 4-variable Modification of Diet in Renal Disease Study equation. RESULTS: At baseline, mean estimated glomerular filtration rate in participants with CKD (n = 304) was 53.0 +/- 6.0 mL/min/1.73 m(2). After an average follow-up of 5.3 +/- 0.8 years, the incidence of a fatal and nonfatal CVD event was lower in participants with CKD receiving lovastatin than in those receiving placebo (adjusted relative risk [RR], 0.31; 95% CI, 0.13-0.72; P = 0.01). Tests for interaction suggested that the benefit of lovastatin was independent of the presence of CKD. Lovastatin did not reduce the annualized mean decrease in estimated glomerular filtration rate (-1.3 +/- 0.07 vs -1.4 +/- 0.07 mL/min/1.73 m(2)/y, respectively; P = 0.1) or the frequency of a > or = 25% decrease in kidney function (adjusted RR, 1.10; 95% CI, 0.96-1.28; P = 0.2) or incident CKD (adjusted RR, 1.04; 95% CI, 0.86-1.27; P = 0.6). LIMITATIONS: Unable to determine the cause and duration of kidney disease, and information regarding proteinuria was not available. CONCLUSIONS:Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND:Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied. STUDY DESIGN: Post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. SETTING & PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial of 5,608 men and 997 women without CVD randomly assigned to treatment with lovastatin or placebo. INTERVENTION: Placebo or lovastatin, 20 mg/d. OUTCOMES & MEASUREMENTS: First major acute cardiovascular event in participants with mild CKD and kidney function loss in persons with or without CKD. Estimated glomerular filtration rate was calculated using the 4-variable Modification of Diet in Renal Disease Study equation. RESULTS: At baseline, mean estimated glomerular filtration rate in participants with CKD (n = 304) was 53.0 +/- 6.0 mL/min/1.73 m(2). After an average follow-up of 5.3 +/- 0.8 years, the incidence of a fatal and nonfatal CVD event was lower in participants with CKD receiving lovastatin than in those receiving placebo (adjusted relative risk [RR], 0.31; 95% CI, 0.13-0.72; P = 0.01). Tests for interaction suggested that the benefit of lovastatin was independent of the presence of CKD. Lovastatin did not reduce the annualized mean decrease in estimated glomerular filtration rate (-1.3 +/- 0.07 vs -1.4 +/- 0.07 mL/min/1.73 m(2)/y, respectively; P = 0.1) or the frequency of a > or = 25% decrease in kidney function (adjusted RR, 1.10; 95% CI, 0.96-1.28; P = 0.2) or incident CKD (adjusted RR, 1.04; 95% CI, 0.86-1.27; P = 0.6). LIMITATIONS: Unable to determine the cause and duration of kidney disease, and information regarding proteinuria was not available. CONCLUSIONS:Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Guruprasad Manjunath; Hocine Tighiouart; Josef Coresh; Bonnie Macleod; Deeb N Salem; John L Griffith; Andrew S Levey; Mark J Sarnak Journal: Kidney Int Date: 2003-03 Impact factor: 10.612
Authors: Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: M Clearfield; E J Whitney; S Weis; J R Downs; D R Shapiro; E A Stein; D J Watson; A Langendörfer; P A Beere; J Stamler; A M Gotto Journal: J Cardiovasc Risk Date: 2000-04
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Elke S Schaeffner; Tobias Kurth; Gary C Curhan; Robert J Glynn; Kathryn M Rexrode; Colin Baigent; Julie E Buring; J Michael Gaziano Journal: J Am Soc Nephrol Date: 2003-08 Impact factor: 10.121
Authors: Marcello Tonelli; Chris Isles; Gary C Curhan; Andrew Tonkin; Marc A Pfeffer; James Shepherd; Frank M Sacks; Curt Furberg; Stuart M Cobbe; John Simes; Timothy Craven; Malcolm West Journal: Circulation Date: 2004-09-13 Impact factor: 29.690
Authors: Lisandro D Colantonio; Usman Baber; Maciej Banach; Rikki M Tanner; David G Warnock; Orlando M Gutiérrez; Monika M Safford; Christoph Wanner; George Howard; Paul Muntner Journal: J Am Soc Nephrol Date: 2014-11-13 Impact factor: 10.121
Authors: Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Michelle C Odden; Ira B Tager; Ron T Gansevoort; Stephan J L Bakker; Linda F Fried; Anne B Newman; Ronit Katz; Suzanne Satterfield; Tamara B Harris; Mark J Sarnak; David Siscovick; Michael G Shlipak Journal: Ann Epidemiol Date: 2013-01-10 Impact factor: 3.797
Authors: Suetonia C Palmer; Jonathan C Craig; Sankar D Navaneethan; Marcello Tonelli; Fabio Pellegrini; Giovanni F M Strippoli Journal: Ann Intern Med Date: 2012-08-21 Impact factor: 25.391